Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB1 | P46663 | 20/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mk0686 SCHEMBL1713029 | 0.91 | BDKRB1 (1.00) | BDKRB1 | |
| Mk0686 SCHEMBL6183541 | 0.91 | BDKRB1 (1.00) | BDKRB1 | |
| SCHEMBL4983157 | 0.85 | BDKRB1 (0.78) | BDKRB1 | |
| SCHEMBL1713230 | 0.85 | BDKRB1 (1.00) | BDKRB1 | |
| SCHEMBL13449215 | 0.85 | BDKRB1 (1.00) | BDKRB1 | |
| SCHEMBL28760016 | 0.84 | BDKRB1 (0.81) | BDKRB1 | |
| SCHEMBL4980902 | 0.84 | BDKRB1 (0.81) | BDKRB1 | |
| SCHEMBL9947991 | 0.84 | BDKRB1 (1.00) | BDKRB1 | |
| SCHEMBL4988970 | 0.84 | BDKRB1 (0.80) | BDKRB1 | |
| SCHEMBL28760032 | 0.84 | BDKRB1 (0.80) | BDKRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1501787-B1 | N-BIPHENYLMETHYL AMINOCYCLOALKANECARBOXAMIDE DERIVATIVES WITH A SUBSTIITUENT ON THE METHYL USEFUL AS BRADYKININ ANTAGONISTS | MERCK & CO INC (US) | 2005-11-09 | — | — | EP | claimed |
| US-12023319-B2 | Carboxylic acid aromatic amides | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2024-07-02 | — | — | US | disclosed |
| US-20230271931-A1 | CARBOXYLIC ACID AROMATIC AMIDES AS ANTAGONISTS OF BRADYKININ B1 RECEPTOR | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2023-08-31 | — | — | US | disclosed |
| US-20230043209-A1 | CARBOXYLIC ACID AROMATIC AMIDES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2023-02-09 | — | — | US | disclosed |
| US-20210317092-A1 | TETRAZOLE CONTAINING COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-10-14 | — | — | US | disclosed |
| US-20190194148-A1 | TETRAZOLE-CONTAINING 1,2-CYCLOPROPANE-CARBOXAMIDES | Bayer Pharma AG (DE) | 2019-06-27 | — | — | US | disclosed |
| US-20190177279-A1 | CARBOXYLIC ACID AROMATIC 1,2-CYCLOPROPYLAMIDES | Bayer Pharma AG (DE) | 2019-06-13 | — | — | US | disclosed |
| US-20190177284-A1 | TETRAZOLYL-CONTAINING CYCLOPROPANECARBOXAMIDES | Bayer Pharma AG (DE) | 2019-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12023319-B2 | Carboxylic acid aromatic amides | DDC, PAH, NAT1 | BDKRB1 1997/4885 |
| US-20210317092-A1 | TETRAZOLE CONTAINING COMPOUNDS | TSLP, IL5, TRPA1 | BDKRB1 820/4885 |
| US-20190177284-A1 | TETRAZOLYL-CONTAINING CYCLOPROPANECARBOXAMIDES | GAP43, PSEN1, PSEN2 | BDKRB1 1549/4885 |
| US-20230043209-A1 | CARBOXYLIC ACID AROMATIC AMIDES | DDC, PAH, NAT1 | BDKRB1 1997/4885 |
| US-20190194148-A1 | TETRAZOLE-CONTAINING 1,2-CYCLOPROPANE-CARBOXAMIDES | HNMT, AANAT, CHRNA5 | BDKRB1 1527/4885 |
| US-20230271931-A1 | CARBOXYLIC ACID AROMATIC AMIDES AS ANTAGONISTS OF BRADYKININ B1 RECEPTOR | BDKRB1, BDKRB2, HCAR1 | BDKRB1 1/4885 |
| US-20190177279-A1 | CARBOXYLIC ACID AROMATIC 1,2-CYCLOPROPYLAMIDES | PAH, DDC, RIMKLA | BDKRB1 1260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.